|Company Name:||ImmunoCellular Therapeutics Ltd|
|Event Title:||Q2 2013 Earnings Call Transcript|
|Event Time:||05:00 PM ET|
Good afternoon everyone and welcome to the ImmunoCellular Therapeutics Second Quarter and 2013 Financial Results Conference Call.
At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference call is being recorded.
At this time I would like to turn the call over to Jane Green ImmunoCellular's Investor At this time I'd like to turn the call over to Jane Green, ImmunoCellular's Investor Relations Group. Ma'am you may begin.
Thank you. Good afternoon. Welcome to ImmunoCellular Therapeutics conference call to discuss the company's second quarter 2013 financial results and corporate update. Today's call is being recorded and is also available via webcast.
Participating on today's call are Chief Executive Officer, Andrew Gengos; Chief Scientific Officer Dr. John Yu and Vice President, Finance and Principal Accounting Officer, David Fractor.
Following this introduction Mr. Gengos will discuss the company's performance and future outlook . Mr. Fractor will review the company's financial results and then the company will take questions.
If you have not received the copy of the second quarter 2013 financial results press release the company issued today, you can obtain them by visiting the company's website www.imuc.com.
ImmunoCellular would like to remind everyone that during the conference call members of the management team will make certain forward-looking statements with statements matters other than historical fact as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual events or results to differ materially from events and include statements about our plans, objectives, expectations and intentions with respect to the timing and potential for success of our scientific approach to cancer immunotherapies and our ICT-107, ICT-121 and ICT-140 products, clinical development efforts, operations financial conditions and other statements that are not historical in nature particularly those that use terms such as will, potential, could, can, belief, intends, continues, plans, expects, project, estimates or similar language.
Important factors known to us that could cause actual events to differ materially from those expressed in such forward-looking statements include those set forth in our most recent annual report on Form 10-K quarterly report on Form 10-Q and other reports filed with the SEC. Please review these and the company's other filings.
Now, I'd like to turn the call over to ImmunoCellular CEO, Andrew Gengos.
President, Chief Executive Officer and Director
Thanks, Jane. Thank you all for joining our call today. We're pleased to have the opportunity to provide an update on our progress in the first half of 2013 and preview upcoming events that have the potential to make this a pivotal year in ImmunoCellular's development.
We look forward to taking your questions following our prepared remarks. I will focus my comments today on describing key next steps and expectations for our development programs and how we envision in our planning for our company's future success. Then I will ask David to review the first quarter, the second quarter financial results. Some of the discussion will be ICT-107 Phase II clinical trial in patients with newly diagnosed glioblastoma.